EDC-9

N/A

Report date: 2024/02/05 13:59:41

Base Information

Drug NameEDC-9

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CD20B cells inhibitors

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsPlasmablastic Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesWisconsin Alumni Research Foundation

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCentrose LLC

Active IndicationsN/A

Inactive IndicationsPlasmablastic Lymphoma

Other Information

ATC CodeN/A